NCT05382208

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 133 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.

Detailed description

This study is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial in approximately 250 people living with HIV who have emphysema. Eligible participants will be randomized in a 1:1 fashion to doxycycline or placebo. Participants will receive 100 mg doxycycline orally or matched placebo twice a day for 72 weeks.

Conditions

• Emphysema
• HIV

Interventions

Type	Name	Description
DRUG	Doxycycline	Doxycycline 100 mg orally twice a day.
DRUG	Placebo	Matching placebo orally twice a day.

Timeline

• Start date: 2022-08-22
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2022-05-19
• Last updated: 2026-01-26

Locations

20 sites across 1 country: United States

Regulatory

• FDA-regulated drug study